Norucholic acid not checked

Dr. Falk Pharma GmbH

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
3 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Primary Sclerosing Cholangitis
Main trialPhase 3
“Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis”In the company’s words, NCT06886360 on ClinicalTrials.gov
Other names
norUrsodeoxycholic acid · norUDCA · NCA · NUC

Other drugs for Primary Sclerosing Cholangitis

All 7 drugs for Primary Sclerosing Cholangitis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Sep 2027 Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
Phase 3Unknown Jan 2025 norUrsodeoxycholic Acid vs Placebo in PSC
Phase 2Unknown Jan 2025 Norursodeoxycholic Acid vs. Placebo in NASH
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Norucholic acid

Following is part of Solo: you see every change to Norucholic acid the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in